Whitefish, MT / July 22, 2014 / Cannabis Technologies Inc. (OTC:CANLF), a leading innovator of technology and science within the cannabis sector, was recently highlighted in a Canadian TV ("CTV") interview discussing the benefits of medical marijuana. As an ovarian cancer survivor, Ms. Shuman has become a leading advocate for the ongoing legalization of cannabis and research conducted by companies in the space, particularly companies like Cannabis Technologies that are working to reduce the time to commercialize cannabis based therapies.
Cannabis Technologies Canada Cheryl Shuman CTV Interview-7-18-14 from TDM Financial on Vimeo.
Cannabis Technologies Inc. is a biopharmaceutical drug discovery and development company focused on cannabinoids that has been dubbed by many as the "Junior GW" in the space. By leveraging its proprietary platform, the company's management team aims to identify new bioactive compounds within the marijuana plant that interact with specific genes to produce meaningful clinical outcomes.
According to Chief Science Officer Sazzad Hossain, the proprietary platform provides the necessary tools to isolate and identify chemical compounds in marijuana in months rather than years. The company will use the platform to isolate compounds targeting specific diseases and conditions and then outsource the early-stage research and trials to get to Phase I as quickly and inexpensively as possible.
Initially, the company plans to focus on the $12 billion ocular disease market, including the $5.7 billion glaucoma market, where its CTI-085 is preparing to undergo Phase I clinical trials shortly. In addition to this area, management has expressed interest in larger markets like pain and inflammation, as well as orphan diseases classified by the FDA like cancers and metabolic diseases.
Just like GW Pharmaceuticals plc (NASDAQ:GWPH), the company also operates a breeding and cultivation division that's responsible for creating the medicines in-house. The proprietary phyto-stock produced by the division sets it apart from competitors that rely on third-parties to manufacture their treatments, since the fully-integrated operations both lower costs and increase quality.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/
SOURCE: Cannabis Financial Network